Skip to content

Prevalence and Hematological Characteristics of Hemoglobinopathies

Prevalence and Hematological Characteristics of Hemoglobinopathies: A Cross-Sectional Study From a Tertiary Care Hospital

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07180836
Enrollment
839
Registered
2025-09-18
Start date
2021-01-15
Completion date
2023-01-20
Last updated
2025-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemoglobinopathies

Keywords

Hemoglobinopathies, Thalassemia, Sickle cell disease

Brief summary

This study aimed to determine the prevalence and hematological characteristics of hemoglobinopathies in Mardan and surrounding districts of Khyber Pakhtunkhwa (KPK), Pakistan. A descriptive cross-sectional design was conducted at Mardan Medical Complex from January 2021 to January 2023. Blood samples were analyzed using High Performance Liquid Chromatography (HPLC) on the Bio-Rad D-10 analyzer, with complete blood counts performed using Sysmex XN1000. A total of 839 participants were enrolled in this study. The study highlights differences in hematological parameters across hemoglobinopathy types and provides region-specific data to inform public health interventions and screening programs.

Detailed description

Hemoglobinopathies are among the most common inherited disorders worldwide, caused by mutations in globin genes affecting hemoglobin synthesis, structure, and function. They are highly prevalent in South Asia, particularly in Pakistan, where beta-thalassemia is the most frequent single-gene disorder. Despite this, there is limited epidemiological data from Khyber Pakhtunkhwa (KPK), especially in Mardan, where consanguineous marriages are common and contribute to disease burden. This descriptive cross-sectional study was conducted over a two-year period (January 2021 to January 2023) at the hematology department of Mardan Medical Complex, Pakistan. All patients referred for hemoglobinopathy testing were included. Blood samples (3 mL EDTA) were collected and analyzed for complete blood counts (hemoglobin, RBC count, hematocrit, MCV, MCH, MCHC) using Sysmex XN1000, and hemoglobin variants were identified using High Performance Liquid Chromatography (Bio-Rad D-10 analyzer). A sickling test was performed in cases with abnormal S-window chromatogram findings. A total of 839 participants were analyzed. Geographic distribution was showed for patients from different nearby regions . This study provides the first comprehensive regional overview of hemoglobinopathies in Mardan, KPK. The findings of our study will emphasize the need for early detection, genetic counseling, and preventive public health strategies, particularly in communities with high rates of consanguinity. These results might support the development of targeted screening and awareness programs to reduce the burden of hemoglobinopathies in Pakistan.

Interventions

OTHERNo Intervention (Observational Study)

This is an observational, cross-sectional study. Patients with suspected or confirmed hemoglobinopathies were evaluated for prevalence and hematological characteristics using laboratory investigations, without any experimental treatment or therapeutic intervention applied.

Sponsors

Bacha Khan Medical College
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* All patients referred to the Hematology Department of Mardan Medical Complex for hemoglobinopathy testing between Jan 2021 - Jan 2023. * Patients of either sex. * Patients who underwent high-performance liquid chromatography (HPLC) and complete blood count (CBC) analysis.

Exclusion criteria

* Patients with incomplete or missing laboratory data (CBC or HPLC). * Patients in whom hemoglobinopathy diagnosis could not be confirmed. * Cases of anemia due to non-hemoglobinopathy causes (e.g., nutritional anemia, chronic disease).

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of Hemoglobinopathies.At the time of diagnosis / Single assessment at enrollmentNumber of patients diagnosed with each hemoglobinopathy type (e.g., β-thalassemia trait, sickle cell disease, HbE).

Secondary

MeasureTime frameDescription
Demographic Distribution of Hemoglobinopathies by Age, Gender, and Geographic AreaAt the time of diagnosis / Single assessment at enrollmentThe study analyzes the demographic characteristics of patients diagnosed with hemoglobinopathies, including distribution by age groups, gender, and geographic location (Mardan and surrounding districts). This outcome helps to identify patterns of disease occurrence and risk groups within the population. Data are derived from patient records and laboratory-confirmed cases.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026